Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPro1595 in MCI with Biomarkers of Inflammation
NCT05321498Phase 2Withdrawn
- Sponsor
- INmune Bio Inc.
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pegipanermin in Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), sponsored by INmune Bio Inc.. Planned start Jun 2023; status: withdrawn.
02
Drugs
pegipanermin
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05321498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321498.